Sterile Processing Pillars: Readiness, Traceability, and Communication

 

There’s never been a greater need for hospitals and other healthcare operations to have full visibility into their assets and how they’re being used in operating room settings and beyond.

In a healthcare landscape that’s seen most healthcare operations adopt some form of electronic health records (EHR) solution, Censis’s solutions can integrate with those capabilities and provide a more intuitive, seamless experience in ensuring that visibility.

To discuss the benefits of Censis solutions like CensiTrac and ScopeTrac Advanced in providing Sterile Processing Departments and Operating Room suites effective visibility of case needs, asset allocations, patient use, and the means to document and communicate facility-specific events related to case picking and utilization, host Shelby Skrhak was joined for this episode of Censis’s podcast by Jacob Long.

Long is a Business Development Manager and Sales Engineer for Censis. He’s personally implemented Censis solutions for years and witnessed firsthand the value for customers that derives from the visibility and traceability the organization’s systems provide via user-friendly and customer-focused application.

The world of sterile processing and perioperative departments is constantly evolving and requires a comprehensive system to fit any facility’s workflow and needs, and Long shared why Censis’s solutions fit that mission and help organization’s reprocess assets readily and safely.

Interested in learning more about Censis Technologies’ surgical asset management platform? Visit Censis.com.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More